Background
==========

Bcl-2/adenovirus E1B 19 kDa-interacting protein3 (BNIP3) is a member of the Bcl-2 family. The common feature among all Bcl-2 family members is the presence of one or several Bcl-2 homology domains, of which four different domains have been identified. The proteins are divided according to these homology domains into pro- and anti-apototic proteins \[[@B1]\]. In the anti-apoptotic group, all four homology domains are present. In BNIP3 and many of the other pro-apoptotic proteins, only the BH3 domain is present and BNIP3 therefore belongs to the BH3-only family. BNIP3 protein is localized on the outside of the mitochondrial membrane. Upon stimulation it integrates into the mitochondrial membrane, leading to permeabilization of the transition pore and a decrease of the mitochondrial membrane potential. This results in chromatin condensation and DNA-fragmentation and finally apoptosis \[[@B2],[@B3]\]. BNIP3-induced cell death is caspase-independent and does not induce cytochrome c release \[[@B2]\]. BNIP3 has also implicated in the induction of autophagy/mitophagy \[[@B4],[@B5]\].

Hypoxia has been described as an important inducer of BNIP3 expression. The transcription factor Hypoxia Inducible Factor (HIF-1α) is the key regulator of the hypoxic response. Under normoxic conditions HIF-1α is hydroxylated, followed by binding to Von Hippel Lindau (VHL) protein and proteosomal degradation. Under hypoxic conditions this hydroxylation does not occur, and in case of VHL mutations proteosomal degradation is prohibited, leading to HIF-1α stabilization, heterodimerization with its constitutively expressed partner HIF-1β and translocation to the nucleus, where it transactivates hypoxia responsive genes by binding to a Hypoxia-Responsive-Element (HRE) in their promoters. Among the target genes of HIF-1α are genes involved in glycolysis, angiogenesis and apoptosis \[[@B6]\]. Previous studies indicated that HIF-1α enhances the expression of BNIP3 \[[@B6]-[@B8]\] and that levels of BNIP3 protein usually parallel mRNA levels \[[@B8]\]. Hypoxia-induced autophagy via BNIP3 has been claimed to be a survival mechanism promoting tumor progression \[[@B9]\].

Decreased levels of BNIP3 mRNA and protein have been found in pancreatic cancer \[[@B10]-[@B12]\], colorectal and gastric cancer \[[@B13]\], and hematopoietic malignancies \[[@B14]\]. On the other hand, increased levels of BNIP3 protein have been described in non-small cell lung cancer, where high expression of BNIP3 protein was linked with a poor prognosis \[[@B15],[@B16]\]. In prostate cancer, there was a significant correlation between cytoplasmic BNIP3 expression and Gleason score, age, and Glut1, and between nuclear BNIP3 expression and HIF-1α \[[@B17]\].

Only a few studies on BNIP3 expression in breast cancer have been published. One study showed high BNIP3 mRNA expression in breast tumors compared to normal tissue, especially in peri-necrotic tumor region \[[@B18]\]. BNIP3 mRNA was also strongly expressed in ductal carcinoma *in situ*(DCIS) and correlated with a high grade phenotype and presence of invasive disease \[[@B19]\]. Another study using an experimental mouse model showed that expression of BNIP3 protein was inversely correlated with the ability of tumor cells to metastasize. Knockdown of BNIP3 increased tumor size and induced metastases \[[@B20]\].

A more recent study \[[@B21]\] suggested that upregulation of BNIP3 protein expression plays a role in breast tumor progression. This study showed an increased disease-free survival in patients with ER-positive BNIP3 nuclear-positive invasive tumors, but no associations with cytoplasmic BNIP3. Furthermore they found no association between HIF-1α and BNIP3.

In the present study we have investigated the expression of BNIP3 in invasive breast cancer at the mRNA and protein level in correlation with the hypoxic response and clinicopathological features. For the hypoxic response, we examined HIF-1α as the key regulator and two of its target genes, Glucose Transporter 1 (Glut-1) and Carbonic Anhydrase 9 (CAIX).

Methods
=======

Human breast tumor samples
--------------------------

Forty specimens of invasive breast carcinoma, surgically resected between 2004 and 2006, were derived from the archives of the Department of Pathology, University Medical Center Utrecht, The Netherlands. Anonymous use of leftover tumor material is part of the standard agreement with patients in our hospital \[[@B22]\], so no explicit ethical approval or informed consent was needed according to Dutch law. The Science Committee of the Department of Pathology of the University Medical Center Utrecht approved the use of frozen section material. For all specimens, formalin-fixed, paraffin embedded material as well as fresh-frozen tissue was available. Thirty cancers were of ductal type, 3 were lobular, 3 ducto-lobular, 3 mucinous and 1 was a medullary carcinoma. All carcinomas were histologically graded according the Bloom and Richardson (B&R) grade \[[@B23],[@B24]\]. Necrosis was noted on the same sections, and the mitotic activity index was assessed as a marker of proliferation as previously described \[[@B25]\]. Estrogen (ER) and progesterone receptor (PR) status were assessed by standard immunohistochemistry.

*In situ*hybridization
----------------------

The probe for BNIP3 mRNA *in situ*hybridization was synthesized by amplification of a 496 bp BNIP3 fragment from human placental cDNA. Primers were selected through Primer Select (version 4.00 1993--1999, DNA Star Inc., Madison, USA) resulting in the forward primer sequence 5\'GCCCGGGATGCAGGAGGAGA and the reverse primer sequence 5\'GAGCAGCAGAGATGGAAGGAAAAC. Primers were purchased from Eurogentec S.A, Seraing, Belgium. PCR conditions were as follows: one denaturing cycle at 95°C for 5 min, followed by 30 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min before a final extension step at 72°C for 10 min.

These primers resulted in a primary PCR product of 496 bp, which was sequenced to assure a 100% nucleotide match with BNIP3 mRNA. A re-PCR was performed to label the BNIP3 PCR-product with digoxigenine, by replacing part of the dTTP in the PCR mix by Dig-11-dUTP (Boehringer-Mannheim GmbH, Mannheim, Germany). Digoxigenine-labeled PCR-products were purified and used as probe for *in situ*hybridization.

Fresh frozen sections of 8 μm were fixed in 4% formaldehyde for 1 h at room temperature. After washing, endogenous peroxidase was blocked with 0.3% H~2~O~2~in phosphate buffered saline (PBS) for 20 min. The cells were made accessible for probes by protein K (0.1 μg/ml in PBS) at 37°C and Triton X100 (0.005% in PBS) treatment. Sections were subsequently dehydrated, air dried and incubated with 25 μl hybridization mix (30% formamide, Tris-EDTA buffer, 20× SSC, yeast tRNA, herring sperm DNA and denatured probe) for 10 min at 47°C on a hot plate to stretch the mRNA, followed by 18 h incubation at 37°C in a humid atmosphere.

After hybridization, slides were washed and the hybridized probe was detected by Polyclonal Rabbit Fab-2 antidigoxigenine/HRP (1:4000 DakoCytomation, Glostrup, Denmark) in PBS/1% bovine serum albumin and visualized by Tyramide FITC (1:50 in amplification diluent (Perkin Elmer, Boston, USA). DNA in the nucleus was visualized with 4 μg/ml propidiumiodide (Sigma Chemicals, St. Louis, USA) in PBS. After washing, the slides were embedded in Fluorescent Mounting Medium (Dakocytomation).

Assessment of *in situ*hybridization
------------------------------------

The pVHL defective cell line RCC10 \[[@B26]\], derived from a sporadic renal clear cell cancer, was used as a positive control for BNIP3 expression, and a pVHL wild type cell line (20) and a slide without the denatured probe were used as negative controls. The results with these control cell lines were checked by RT-PCR with both BNIP3-specific primers and primers for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as household gene.

Hybridized tissues were analyzed using a confocal laser scanning microscope (Leica TCS, Rijswijk, The Netherlands). Stromal macrophages and lymphocytes served as internal control for BNIP3 expression, as they showed a similar strong mRNA expression in all slides, as confirmed by immunohydrido double staining for CD68 respectively CD3 (data not shown), whereas tumor BNIP3 signal intensity differed between the different samples. Samples were binary scored as negative/weak or positive.

Immunohistochemistry
--------------------

Serial sections of 4 μm of paraffin embedded material of each specimen were deparaffinized and rehydrated in graded alcohol. Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide in PBS for 20 min. Antigen retrieval was performed by boiling the slides 20 min in 10 mM citrate buffer (pH 6.0) for BNIP3, CAIX and Glut-1, and in EDTA buffer (pH 9.0) for HIF-1α immunohistochemistry. To avoid non-specific binding of BNIP3, slides were pre-incubated with 10% normal swine serum in PBS. Thereafter slides were incubated with antibodies against BNIP3 (Rabbit polyclonal BNIP3, Biocarta Europe GmbH, Hamburg, Germany, dilution 1:1000), CAIX (Rabbit polyclonal, Abcam, Cambridge, UK, dilution 1:1000), HIF-1α (Mouse monoclonal, BD Transduction Laboratories, Lexington, USA dilution 1:50) or Glut-1 (Dako, dilution 1:200).

Incubation with anti-BNIP3 and anti-HIF-1α was done overnight at 4°C, and with anti-CAIX and anti-Glut-1 at room temperature for 1 h.

After incubation, slides were washed and incubated with Powervision (Immunologic, Duiven, The Netherlands), final staining was developed by adding 3,3 diaminobenzidine tetrahydrochloric acid in PBS (1.5% H~2~O~2~) and slides were counterstained with haematoxylin.

A renal clear cell carcinoma (CAIX, Glut-1, BNIP3), an invasive breast cancer (HIF-1α,) and placental tissue (BNIP3) were used as controls for immunohistochemistry \[[@B27]\]. Negative controls were obtained by omission of the primary antibodies.

Quantification of immunohistochemistry
--------------------------------------

All slides were scored independently by two pathologists (EAK/PJvD). Samples were binary scored as negative/weak or positive. When possible, both the tumor and the benign tissue were scored. Glut-1 as well as CAIX staining were scored as positive when membrane staining was seen. For HIF-1α the percentage of positive nuclei was scored as well as the topography: perinecrotic, diffuse or a combination of both. Only homogenously and darkly stained nuclei were considered and a percentage of ≥ 1% positive nuclei was considered positive in line with previous studies. \[[@B28]\].

Statistical analysis
--------------------

Fisher\'s exact test (GraphPad Instat, version 3.01, Graphpad Software Inc., San Diego, USA) was used to test the correlation between BNIP3 *in situ*hybridization and immunohistochemistry and the other immunohistochemical and clinicopathological features. For HIF-1α, the traditional threshold of 5% was used. Two-sided p-values \< 0.05 were considered significant.

Results
=======

*In situ*hybridization
----------------------

The positive control RCC10 cell line showed an intense signal in the cytoplasm (Fig. [1a](#F1){ref-type="fig"}), whereas cells of the pVHL wild type cell line showed no or very low BNIP3-mRNA signal (Fig. [1b](#F1){ref-type="fig"}). RT-PCR for BNIP3 band resulted in a much more intense band in the pVHL defective cell line compared to the pVHL intact cell line (Fig [2](#F2){ref-type="fig"}). As expected this effect was not seen for the household gene *GAPDH*.

![***In situ*hybridization for BNIP3-mRNA**. BNIP3-mRNA (green) in control cells. Nuclei are visualized with Propidiumiodide (red). (a) BNIP3 mRNA expression in the pVHL defective cell line RCC10. (b) BNIP3 mRNA expression in a pVHL wild type cell line.](1471-2407-9-175-1){#F1}

![**RT-PCR results in duplicate**. A pVHL wild type cell line with (a) BNIP3 amplicon compared to a pVHL defective cell line with (b) BNIP3 amplicon. As control lane (c) shows a pVHL wild type cell line with GAPDH amplicon, compared to a pVHL defective cell line (d) with GAPDH amplicon. Lane (e) shows negative H~2~O control, and (f) and (g) show positive controls with placental cDNA with BNIP3 amplicon (f) and with GAPDH amplicon (g).](1471-2407-9-175-2){#F2}

Sixteen of the 40 breast carcinomas (40%) were positive for BNIP3 mRNA. In all cases the signal was strong throughout the tumor, and tumor cell staining was often granular (Fig [3a](#F3){ref-type="fig"}), compared to the more diffuse signal in macrophages. In the remaining 60% of cases, tumor cells were negative or had only a very weak cytoplasmic signal (Fig [3c](#F3){ref-type="fig"}), whereas the macrophages still had their diffuse strong signal.

![***In situ*hybridization and immunohistochemistry for BNIP3 (original magnification 20×)**. (a) BNIP3 mRNA expression in a positive tumor and (b) strong BNIP3 protein expression in the same tumor. (c) BNIP3 mRNA negative tumor with presence of positive stromal macrophages as internal controls and (d) absence of BNIP3 protein expression in the same tumor.](1471-2407-9-175-3){#F3}

Immunohistochemistry
--------------------

Twenty-three out of 40 tumors (57%) were positive for BNIP3 protein (Fig [3b](#F3){ref-type="fig"}). Most of these tumors had a diffusely positive cytoplasmic signal throughout the tumor. The remaining 17 cases were negative or had a very weak expression (Fig [3d](#F3){ref-type="fig"}). Expression of BNIP3 protein correlated with BNIP3 mRNA expression (p = 0.022).

In 35 cases there was sufficient adjacent normal breast tissue that could be examined. In 8 of these 35 cases, the normal breast tissue showed nuclear staining whereas this was rarely seen in tumor cells (Fig. [4](#F4){ref-type="fig"}). When tumor cells were strongly positive, the adjacent normal tissue showed a clearly lower signal in 13/20 (65%) of cases, whereas the normal tissue showed a strong signal similar to the tumor cells in 7/20 (35%) of cases. In 6/15 (40%) of cases where tumor cells had a very low signal or no BNIP3 expression, the normal breast tissue showed more BNIP3 expression than the tumor cells.

![Immunohistochemistry for BNIP3 in 2 cases of invasive breast cancer (original magnification 40×) showing nuclear staining in adjacent normal breast tissue (a and c), while tumor cells of the same specimens show only cytoplasmic expression (b and d).](1471-2407-9-175-4){#F4}

HIF-1α was positive in 24/40 tumors (60%), 8 of them in a perinecrotic and 16 in a diffuse pattern. CAIX and Glut-1 membrane staining were seen in 16/40 (40%) and 15/40 (38%) of cancers, respectively. Figure [5](#F5){ref-type="fig"} shows some representative examples. There was a significant correlation between expression of Glut-1 and CAIX (p = 0.018). CAIX and Glut-1 expression was absent in normal tissue surrounding the tumors.

![**Representative examples of immunohistochemical staining for (a) diffuse HIF-1α, (b) perinecrotic HIF-1α, (c) CAIX and (d) Glut-1 in an invasive breast cancer (b, c, d same case)**. Original magnification 40×.](1471-2407-9-175-5){#F5}

Positive HIF-1α staining was typically associated with necrosis. Of the 24 HIF-1α positive tumors, 12 showed CAIX (p = 0.006) and 12 showed Glut-1 expression (p = 0.017), especially those with necrosis. Most diffusely positive HIF-1α cases were Glut-1 negative (69%); 50% were negative for CAIX.

Neither BNIP3 mRNA nor protein status showed significant relations with HIF-1α status (Table [1](#T1){ref-type="table"}). BNIP3 was however, more often although not significantly expressed in diffusely HIF-1α positive cases (10/16, 62%) than in perinecrotic HIF-1α positive cases (2/6, 33%) (p = 0.353). BNIP3 protein and mRNA expression failed to correlate with CAIX or Glut-1 expression (Table [1](#T1){ref-type="table"}).

###### 

Association between BNIP3 mRNA and protein expression and the hypoxia response proteins in invasive breast cancer (n = 40).

                                               BNIP3 mRNA          BNIP3 protein                
  ------------ ------------------------------- ------------ ------ --------------- ----- ------ ---------
               Grouping                        Low          High   p-value         Low   High   p-value
                                                                                                
  **HIF-1α**   0                               12           4      0.188           5     11     0.332
                                                                                                
               ≥ 1%                            12           12                     12    12     
                                                                                                
  **Glut-1**   Negative/cytoplasmic staining   17           8      0.204           10    15     0.749
                                                                                                
               Membrane staining               7            8                      7     8      
                                                                                                
  **CAIX**     Negative/cytoplasmic staining   16           8      0.338           9     15     0.522
                                                                                                
               Membrane staining               8            8                      8     8      

Clinicopathological features
----------------------------

As shown in Table [2](#T2){ref-type="table"}, tumors negative for BNIP3 protein, had a significantly higher frequency of axillary lymph node metastases than tumors with BNIP3 expression (82% vs 39%, p = 0.010). For BNIP3 mRNA the same inverse association was seen (p = 0.001). The mitotic index showed a similar inverse association with BNIP3 protein expression (p = 0.027). Tumor size, histological grading, necrosis, ER and PR were not significantly associated with BNIP3 protein expression (see Table [2](#T2){ref-type="table"}), as for BNIP3 mRNA.

###### 

Association of BNIP3 mRNA and protein expression with clinicopathological features in invasive breast cancer (n = 40).

                           BNIP3 mRNA        BNIP3 protein             
  ------------------------ ------------ ---- --------------- ---- ---- -------
  **Lymph node status**                                                
   **Negative**            5            12   0.001           3    14   0.009
   **Positive**            19           4                    15   9    
  **MAI (2 mm**^2^**)**                                                
   **1--12**               9            9    0.335           4    14   0.027
   **≥ 13**                15           7                    13   9    
  **ER**                                                               
   **Negative**            7            6    0.733           5    8    1.000
   **Positive**            17           10                   12   15   
  **PR**                                                               
   **Negative**            12           7    0.755           10   9    0.337
   **Positive**            12           9                    7    14   
  **Tumor size**                                                       
   **0--2 cm**             7            6    0.733           3    10   0.103
   **\> 2 cm**             17           10                   14   13   
  **Histological grade**                                               
   **I/II**                11           10   0.349           6    15   0.108
   **III**                 13           6                    12   8    
  **Necrosis**                                                         
   **Negative**            17           9    0.500           10   16   0.520
   **Positive**            7            7                    7    7    

\* MAI: mitotic activity index, ER: estrogen receptor, PR: progesterone receptor.

Discussion
==========

The aim of the present study was to investigate the expression of BNIP3 in invasive breast cancer at the mRNA and protein level in correlation with the hypoxic response and clinicopathological features. Twenty three out of 40 tumors (57%) were positive for BNIP3 protein. The remaining 17 cases were negative or had a very weak expression. Expression of BNIP3 protein correlated with BNIP3 mRNA expression (p = 0.022).

To test the hypoxic response in invasive breast carcinomas in relation to BNIP3, we also examined the expression of HIF-1α and its target genes Glut-1 and CAIX \[[@B29]-[@B31]\]. CAIX and Glut-1 showed the expected positive correlation with HIF-1α (p = 0.006, p = 0.017, respectively), especially with perinecrotic HIF-1α \[[@B31]\], indicating that the study group is large enough to study the hypoxic response. Of all tumors tested, 16 showed BNIP3 mRNA expression. Twelve (75%) of these also had HIF-1α expression. The remaining 25% had no HIF-1α, but did show BNIP3 mRNA. Thereby, the correlation between HIF-1α protein and BNIP3 was not significant at the mRNA or protein level. In a previous study \[[@B19]\], perinecrotic expression of BNIP3 mRNA and protein was reported in DCIS, but it was not mentioned whether this was also seen in invasive cancer, which we did not find. Also in another recent study \[[@B21]\] there was no association between HIF-1α and BNIP3. There are therefore no firm clues that BNIP3 expression in invasive breast cancer is hypoxia dependent. Induction of BNIP3 may however also occur through non-hypoxic stimulation. The zinc-finger protein PLAGL2 is for example able to increase BNIP3 levels, but is independent of the hypoxia-responsive element in the BNIP3-promoter \[[@B32]\]. In this current study twenty four tumors (60%) had no BNIP3 mRNA expression. A likely explanation for the absence of BNIP3 mRNA could be methylation of the BNIP3-promoter, which would result in silencing of the gene. This has been shown in pancreatic adenocarcinoma where the promoter of *BNIP3*turned out to be methylated in all BNIP3-negative pancreatic cancer cell lines and in eight out of 10 pancreatic adenocarcinoma samples \[[@B12]\]. Impaired hypoxia induced BNIP3 expression has also been detected in other malignancies. Sixty six percent of the primary colorectal and 49% of the gastric cancers showed BNIP3 methylation \[[@B13],[@B14]\]. Also in haematological malignancies methylation of the BNIP3 gene has been described, although less frequently \[[@B14]\]. BNIP3 promoter methylation in breast cancer has however not yet been described.

Another mechanism of mediation of BNIP3 activity may be intranuclear sequestration of BNIP3 protein, that has been reported in glial cells of the normal brain and in glioblastoma multiforme \[[@B33]\]. In our study, we did not find nuclear BNIP3 protein in tumors cells, but in 23% of cases in adjacent normal breast tissue. This fits with the concept of intranuclear sequestration of BNIP3 in normal breast tissue, but the exact mechanism remains unclear and should be part of further research.

By examining the relationship between BNIP3 expression and clinicopathological features, we found a highly significant inverse correlation between BNIP3 expression and presence of lymph node metastases, both on the protein level and mRNA level, this in contrast to a previous study \[[@B21]\]. Of the 24 BNIP3 mRNA negative tumors, 79% had axillary lymph node metastases, whereas this was only 25% in the BNIP3 mRNA positive group. Furthermore, BNIP3 expression correlated with the mitotic index, which is known to be a strong prognostic indicator in breast cancer \[[@B25],[@B34]\]. Survival analysis is not yet possible because of the short follow-up time, but 3 patients had distant metastases in the lung, bones or brain at the time of completing this study. In all three cases there was no BNIP3 mRNA. All this implies that BNIP3 expression could be a prognostic indicator in breast cancer.

Conclusion
==========

BNIP3 expression is lost in a significant proportion of invasive breast cancers, and loss of BNIP3 expression correlated with poor prognostic features such as positive lymph node status and high proliferation, but not with the hypoxic response. BNIP3 inactivation may therefore be involved in breast carcinogenesis and deserves to be studied as a potential prognostic indicator in breast cancer.
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